CYSTEA-BONE Clinical Study

Civil Hospices of Lyon

Status: Enrolling

Conditions: Nephropathic Cystinosis

Treatments: Other: Blood sampling

Study type: Observational

Funder types: Other

Identifiers

NCT03919981

2019-A00166-51 (Other Identifier)

69HCL18_0685

Details and patient eligibility

About

Nephropathic Cystinosis (NC) is an orphan inherited autosomal recessive disease characterised as a generalized lysosomal storage disease due to a deficiency of the cystine lysosomal transport protein, cystinosin.

Patients with NC usually receive cysteamine. Bone impairment was recently recognized as a late complication of NC, occurring at adolescence or early adulthood. Even though the exact underlying pathophysiology is unclear, at least six hypotheses are discussed, and mainly cysteamine toxicity and/or direct bone effect of the Cystinosin (CTNS) mutation. Because of the potential dramatic impact on quality of life of this novel complication, research should aim to better understand bone disease in NC.

The primary objective of this study is to evaluate the action of cysteamine on osteoclastic differentiation and resorption activity of NC patients, depending on the underlying genotype. The Secondary objective is to describe the clinical bone status of NC patients depending on their underlying genotype.

Enrollment: 50 estimated patients

Sex: All

Ages: 2+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female subjects with confirmed diagnosis of nephropathic cystinosis (defined by clinical signs, White Blood Cells (WBC) cystine level and/or mutation), currently receiving oral cysteamine.
• Age > 2 years.
• Subjects and/or their parents/ legal guardian must provide non opposition prior to participation in the study.

Exclusion criteria

• Subjects who, in the opinion of the Investigator, are not able or willing to comply with the protocol.

Trial design

50 participants in 1 patient group

nephropathic cystinosis patients receiving cysteamine

Description:

nephropathic cystinosis patients receiving cysteamine. The blood samples of the group will be used to evaluate the action of cysteamine on osteoclastic differentiation and resorption activity of NC patients, depending on the underlying genotype.

Treatment:

Other: Blood sampling